Harmony Biosciences Holdings (HRMY) Finished Goods (2023 - 2024)
Harmony Biosciences Holdings (HRMY) posted Finished Goods of $2.8 million for Q4 2024, down 17.04% sequentially from $3.3 million in Q3 2024, and up 21.11% YoY from $2.3 million in Q1 2024.
Harmony Biosciences Holdings (HRMY) Finished Goods (2023 - 2024) Analysis & Trends
Harmony Biosciences Holdings has reported Finished Goods for 2 years, with the latest figure at $2.8 million in Q4 2024.
- Quarterly Finished Goods rose 21.11% year-over-year to $2.8 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $2.8 million (up 21.11% YoY) and the FY2024 annual result came in at $2.8 million, up 21.11% from the prior year.
- Finished Goods fell to $2.8 million in Q4 2024 per HRMY's latest filing, from $3.3 million in the prior quarter.
- Over five years, Finished Goods peaked at $3.3 million in Q3 2024 and troughed at $2.3 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Harmony Biosciences Holdings | 2.22 Bn | 1.41 Bn | 198.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 2.77 Mn |
| Sep 30, 2024 | 3.33 Mn |
| Jun 30, 2024 | 2.76 Mn |
| Mar 31, 2024 | 3.10 Mn |
| Dec 31, 2023 | 2.28 Mn |